Personalized Medicine Through GPCR Pharmacogenomics

Research output: Chapter in Book/Report/Conference proceedingBook chapterResearchpeer-review

Standard

Personalized Medicine Through GPCR Pharmacogenomics. / Hauser, Alexander Sebastian.

Personalized Medicine Through GPCR Pharmacogenomics. ed. / Terry Kenakin. Elsevier, 2021.

Research output: Chapter in Book/Report/Conference proceedingBook chapterResearchpeer-review

Harvard

Hauser, AS 2021, Personalized Medicine Through GPCR Pharmacogenomics. in T Kenakin (ed.), Personalized Medicine Through GPCR Pharmacogenomics. Elsevier. https://doi.org/10.1016/B978-0-12-820472-6.00100-6

APA

Hauser, A. S. (2021). Personalized Medicine Through GPCR Pharmacogenomics. In T. Kenakin (Ed.), Personalized Medicine Through GPCR Pharmacogenomics Elsevier. https://doi.org/10.1016/B978-0-12-820472-6.00100-6

Vancouver

Hauser AS. Personalized Medicine Through GPCR Pharmacogenomics. In Kenakin T, editor, Personalized Medicine Through GPCR Pharmacogenomics. Elsevier. 2021 https://doi.org/10.1016/B978-0-12-820472-6.00100-6

Author

Hauser, Alexander Sebastian. / Personalized Medicine Through GPCR Pharmacogenomics. Personalized Medicine Through GPCR Pharmacogenomics. editor / Terry Kenakin. Elsevier, 2021.

Bibtex

@inbook{45368400d932499e936c98a51e961bd7,
title = "Personalized Medicine Through GPCR Pharmacogenomics",
abstract = "Understanding the magnitude of response to a given treatment at an individual level is one of the most important and long-standing challenges in personalized medicine and pharmacogenomics. A great deal of effort has been placed on understanding variation in drug transport and metabolism. However, little is known about how variability in receptor drug targets affects treatment regimens. G protein-coupled receptors (GPCRs) are the single most prevalent drug target family. Elucidating the spectrum and impact of how a GPCR variant influences ligand binding, signaling and, ultimately, therapeutic effect is vital and could serve as the next important step for understanding variability in drug response.",
keywords = "Faculty of Health and Medical Sciences",
author = "Hauser, {Alexander Sebastian}",
year = "2021",
doi = "10.1016/B978-0-12-820472-6.00100-6",
language = "English",
editor = "Terry Kenakin",
booktitle = "Personalized Medicine Through GPCR Pharmacogenomics",
publisher = "Elsevier",
address = "Netherlands",

}

RIS

TY - CHAP

T1 - Personalized Medicine Through GPCR Pharmacogenomics

AU - Hauser, Alexander Sebastian

PY - 2021

Y1 - 2021

N2 - Understanding the magnitude of response to a given treatment at an individual level is one of the most important and long-standing challenges in personalized medicine and pharmacogenomics. A great deal of effort has been placed on understanding variation in drug transport and metabolism. However, little is known about how variability in receptor drug targets affects treatment regimens. G protein-coupled receptors (GPCRs) are the single most prevalent drug target family. Elucidating the spectrum and impact of how a GPCR variant influences ligand binding, signaling and, ultimately, therapeutic effect is vital and could serve as the next important step for understanding variability in drug response.

AB - Understanding the magnitude of response to a given treatment at an individual level is one of the most important and long-standing challenges in personalized medicine and pharmacogenomics. A great deal of effort has been placed on understanding variation in drug transport and metabolism. However, little is known about how variability in receptor drug targets affects treatment regimens. G protein-coupled receptors (GPCRs) are the single most prevalent drug target family. Elucidating the spectrum and impact of how a GPCR variant influences ligand binding, signaling and, ultimately, therapeutic effect is vital and could serve as the next important step for understanding variability in drug response.

KW - Faculty of Health and Medical Sciences

U2 - 10.1016/B978-0-12-820472-6.00100-6

DO - 10.1016/B978-0-12-820472-6.00100-6

M3 - Book chapter

BT - Personalized Medicine Through GPCR Pharmacogenomics

A2 - Kenakin, Terry

PB - Elsevier

ER -

ID: 279288718